

Irit Avivi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1755416/irit-avivi-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

164
papers

4,616
citations

24
h-index

66
g-index

178
ext. papers

6,434
ext. citations

4.8
avg, IF

5.24
L-index

#	Paper	IF	Citations
164	BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses.. <i>British Journal of Haematology</i> , 2022 ,	4.5	4
163	Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.. <i>Annals of Hematology</i> , 2022 , 101, 755	3	0
162	Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells. <i>European Journal of Haematology</i> , 2022 , 108, 52-60	3.8	2
161	COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge.. <i>Cancer Cell</i> , 2022 ,	24.3	0
160	Low FXIII activity levels in intensive care unit hospitalized COVID-19 patients. <i>Thrombosis Journal</i> , 2021 , 19, 79	5.6	2
159	Automated Digital Morphometry of Peripheral Blood Smears Detects Both Infrequent Events and Cellular Population Patterns in Myelodysplastic Syndrome. <i>Blood</i> , 2021 , 138, 3999-3999	2.2	
158	Sequential Therapy with Fityc Preparative Regimen for Patients with Primary Refractory AML - a Single Center Retrospective Analysis. <i>Blood</i> , 2021 , 138, 2860-2860	2.2	
157	Multiple Myeloma Oligosecretory Relapse, a Non-Negligible Phenomenon. Frequency, Clinical Characteristics and Outcomes in a Single Center. <i>Blood</i> , 2021 , 138, 3772-3772	2.2	
156	Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2021 , 138, 2606-2606	2.2	0
155	Performance Evaluation Study of a Novel Digital Microscopy System for the Quantitative Analysis of Bone Marrow Aspirates. <i>Blood</i> , 2021 , 138, 4000-4000	2.2	
154	Using Machine Learning Methods to Explore the Role of Non-Coding RNAs in DLBCL. <i>Blood</i> , 2021 , 138, 4324-4324	2.2	
153	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2021 , 137, 3165-3173	2.2	274
152	Lower Patient Anxiety and Unchanged Levels of Adherence to Hemato-Oncologic Treatment in Response to New Measures to Reduce Hospital Exposure Risk to COVID-19. <i>Patient Preference and Adherence</i> , 2021 , 15, 945-952	2.4	0
151	Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 3540-3549	8.8	16
150	Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells. <i>Frontiers in Oncology</i> , 2021 , 11, 646971	5.3	2
149	Diabetes, but not pre-diabetes, is associated with shorter time to second-line therapy and worse outcomes in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2785-2792	1.9	1
148	Peripheral B cells repress B-cell regeneration in aging through a TNF- β /IGFBP-1/IGF-1 immune-endocrine axis. <i>Blood</i> , 2021 , 138, 1817-1829	2.2	1

147	Feasibility of CD24/CD11b as a Screening Test for Hematological Malignancies. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	1
146	Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021 , 194, 690-700	4.5	12
145	Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience. <i>Leukemia and Lymphoma</i> , 2021 , 62, 118-124	1.9	8
144	Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1031-1037	4.4	5
143	Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation. <i>Translational Oncology</i> , 2021 , 14, 100977	4.9	4
142	Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients. <i>Journal of Neuro-Oncology</i> , 2021 , 151, 211-220	4.8	1
141	Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma. <i>British Journal of Haematology</i> , 2021 , 192, e1-e4	4.5	3
140	Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review. <i>European Journal of Haematology</i> , 2021 , 106, 184-195 ^{3.8}	3.8	6
139	Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy. <i>British Journal of Haematology</i> , 2021 , 193, 52-62	4.5	1
138	Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study. <i>Therapeutic Advances in Hematology</i> , 2021 , 12, 20406207211035272	5.7	2
137	Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study. <i>Leukemia Research</i> , 2021 , 101, 106498	2.7	1
136	Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. <i>Nature Medicine</i> , 2021 , 27, 491-503	50.5	27
135	Toxicity and efficacy of chimeric antigen receptor T-cell in patients with diffuse large B cell lymphoma above the age of 70 years compare to younger patients - a matched control multi-center cohort study. <i>Haematologica</i> , 2021 ,	6.6	3
134	Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2021 , 195, 186-193	4.5	28
133	Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 788-794		39
132	[F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 1	8.8	3
131	Extracellular Vesicles Derived from Chimeric Antigen Receptor-T Cells: A Potential Therapy for Cancer. <i>Human Gene Therapy</i> , 2021 , 32, 1224-1241	4.8	3
130	Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021 , 195, 388-398	4.5	8

129	Evaluation of Scopio Labs X100 Full Field PBS: The first high-resolution full field viewing of peripheral blood specimens combined with artificial intelligence-based morphological analysis. <i>International Journal of Laboratory Hematology</i> , 2021 , 43, 1408-1416	2.5	5
128	Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma. <i>BMC Cancer</i> , 2020 , 20, 489	4.8	1
127	Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study. <i>Annals of Hematology</i> , 2020 , 99, 1273-1281	3	4
126	The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants. <i>British Journal of Haematology</i> , 2020 , 189, e31-e33	4.5	3
125	Bortezomib washout duration prior to stem cell mobilization in patients with newly diagnosed multiple myeloma. <i>European Journal of Haematology</i> , 2020 , 105, 30-34	3.8	1
124	Rituximab is not associated with increased risk of second primary malignancies in Israeli patients with diffuse large B cell lymphoma treated with RCHOP regimen. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2638-2644	1.9	
123	Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group. <i>American Journal of Hematology</i> , 2020 , 95, 465-471	7.1	5
122	Kinetics of pre-myelodysplastic syndromes blood values correlate with disease risk and survival. <i>Hematological Oncology</i> , 2020 , 38, 782-791	1.3	
121	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020 , 95, 503-509	7.1	6
120	Discovery of tumoricidal DNA oligonucleotides by response-directed in vitro evolution. <i>Communications Biology</i> , 2020 , 3, 29	6.7	0
119	A Novel Approach to Blood Smear Analysis Based on Specimen Topology: Implications for Human and Artificial Intelligence Decision Making. <i>Blood</i> , 2020 , 136, 8-9	2.2	
118	A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial. <i>Blood</i> , 2020 , 136, 19-20	2.2	0
117	Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8012-8012	2.2	5
116	Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity. <i>Cancer Immunology Research</i> , 2020 , 8, 1485-1495	12.5	9
115	The impact of anti-bacterial prophylaxis on the outcome of patients treated with venetoclax-based regimens for relapsed/refractory plasma cell dyscrasias: Real-life data. <i>Leukemia Research</i> , 2020 , 97, 106429	2.7	2
114	Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, e850-e857	2	0
113	Characteristics and outcomes of adults with cytomegalovirus-associated thrombocytopenia: a case series and literature review. <i>British Journal of Haematology</i> , 2020 , 191, 863-867	4.5	2
112	Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban. <i>Acta Haematologica</i> , 2020 , 143, 266-271	2.7	4

111	Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. <i>Annals of Hematology</i> , 2020 , 99, 1251-1255	3	6
110	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1885-1893	1.9	2
109	Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study. <i>American Journal of Hematology</i> , 2019 , 94, 992-1001	7.1	2
108	Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study. <i>Annals of Hematology</i> , 2019 , 98, 1927-1932	3	33
107	Depletion of B cells rejuvenates the peripheral B-cell compartment but is insufficient to restore immune competence in aging. <i>Aging Cell</i> , 2019 , 18, e12959	9.9	11
106	Current treatment of lymphoma in pregnancy. <i>Expert Review of Hematology</i> , 2019 , 12, 449-459	2.8	3
105	Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms. <i>European Journal of Haematology</i> , 2019 , 102, 504-508	3.8	4
104	Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. <i>Haematologica</i> , 2019 , 104, 1798-1803	6.6	4
103	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019 , 60, 118-123	1.9	12
102	Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2019 , 6, e448-e458	14.6	100
101	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2019 , 6, e459-e469	14.6	104
100	Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. <i>American Journal of Hematology</i> , 2019 , 94, 1132-1140	7.1	13
99	Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study. <i>Hematological Oncology</i> , 2019 , 37, 569-577	1.3	10
98	Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study. <i>Lancet Haematology</i> , 2019 , 6, e551-e561	14.6	28
97	Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data. <i>Blood</i> , 2019 , 134, 5321-5321	2.2	2
96	Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma. <i>Blood</i> , 2019 , 134, 243-243	2.2	32
95	Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study. <i>Blood</i> , 2019 , 134, 3180-3180	2.2	
94	Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study. <i>Blood</i> , 2019 , 134, 5654-5654	2.2	

93	Is the Achievement of Pre-Autologous Transplant CR Necessary Indeed in Refractory/ Relapsed DLBCL Patients? a Retrospective Multicenter Study. <i>Blood</i> , 2019 , 134, 5703-5703	2.2	
92	Personalized Ubiquitination Signatures for Predicting Response to Proteasome Inhibitor-Based Therapy of MM Patients. <i>Blood</i> , 2019 , 134, 3371-3371	2.2	
91	Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy. <i>Molecular Cancer Research</i> , 2019 , 17, 2331-2340	6.6	11
90	Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. <i>Lancet Haematology</i> , 2019 , 6, e67-e78	14.6	95
89	Hematological malignancies during pregnancy. <i>Molecular and Clinical Oncology</i> , 2019 , 10, 3-9	1.6	3
88	Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1001-1009	4.4	17
87	Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome. <i>Leukemia Research</i> , 2018 , 68, 9-14	2.7	10
86	Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 739-748	7.4	6
85	Community-acquired respiratory infections are common in patients with non-Hodgkin lymphoma and multiple myeloma. <i>Supportive Care in Cancer</i> , 2018 , 26, 2425-2431	3.9	6
84	Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literature. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018 , 25, 11-17	2.7	4
83	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. <i>British Journal of Haematology</i> , 2018 , 180, 831-839	4.5	24
82	Toxicity and efficacy of autologous hematopoietic cell transplantation in elderly patients with aggressive lymphoma: a historical prospective study. <i>Annals of Hematology</i> , 2018 , 97, 459-466	3	1
81	Extended vs Bolus Infusion of Broad-Spectrum β -Lactams for Febrile Neutropenia: An Unblinded, Randomized Trial. <i>Clinical Infectious Diseases</i> , 2018 , 67, 1153-1160	11.6	22
80	Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis. <i>Leukemia and Lymphoma</i> , 2018 , 59, 610-616	1.9	17
79	Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1163-1171	1.9	3
78	Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?. <i>European Journal of Haematology</i> , 2018 , 101, 502-507	3.8	4
77	Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study. <i>American Journal of Hematology</i> , 2018 , 93, E238-E241	7.1	2
76	High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. <i>British Journal of Haematology</i> , 2018 , 182, 807-815	4.5	8

75	Hodgkin lymphoma of the gastrointestinal tract in patients with inflammatory bowel disease: Portrait of a rare clinical entity. <i>Leukemia Research</i> , 2018 , 71, 1-5	2.7	8
74	Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group. <i>Blood</i> , 2018 , 132, 3295-3295	2.2	1
73	Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study. <i>Blood</i> , 2018 , 132, 1972-1972	2.2	1
72	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. <i>Blood</i> , 2018 , 132, 4452-4452	2.2	2
71	Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience. <i>Blood</i> , 2018 , 132, 3259-3259	2.2	1
70	A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8021-8021	2.2	16
69	Single cell analysis of multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8026-8026	2.2	
68	Prothrombin Complex Concentrate Is Safe and Effective for Achieving Hemostasis in the Setting of Urgent Surgery for Patients Treated with Direct Xa Inhibitors. <i>Blood</i> , 2018 , 132, 2541-2541	2.2	
67	Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients. <i>Blood</i> , 2018 , 132, 2004-2004	2.2	
66	CT findings are highly predictive for perforation in patients with diffuse large B-cell lymphoma involving the intestines. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1878-1883	1.9	0
65	Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. <i>Nature Medicine</i> , 2018 , 24, 1867-1876	50.5	105
64	Ten Things to Know About Primary Mediastinal B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1959-1960	4.7	
63	Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center. <i>Acta Haematologica</i> , 2018 , 140, 194-202	2.7	2
62	Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study. <i>Annals of Hematology</i> , 2017 , 96, 271-278	3.2	5
61	Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation-a retrospective national multicenter study. <i>Annals of Hematology</i> , 2017 , 96, 575-579	3	5
60	Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2017 , 102, 874-882	6.6	43
59	Familial chronic lymphocytic leukemia in Israel: A disproportionate distribution among Ashkenazi Jews. <i>European Journal of Haematology</i> , 2017 , 99, 51-55	3.8	
58	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017 , 178, 571-582	4.5	39

57	Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone. <i>Annals of Hematology</i> , 2017 , 96, 461-467	3	7
56	Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. <i>Haematologica</i> , 2017 , 102, 1913-1922	6.6	34
55	The management of hodgkin lymphomas in pregnancies. <i>European Journal of Haematology</i> , 2017 , 99, 385-391	3.8	10
54	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017 , 377, 2531-2544	59.2	2326
53	Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. <i>Hematological Oncology</i> , 2017 , 35, 734-740	1.3	5
52	Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia. <i>Blood</i> , 2017 , 130, 833-833	2.2	11
51	Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study. <i>Leukemia and Lymphoma</i> , 2016 , 57, 63-9	1.9	20
50	Polymicrobial pulmonary infection in patients with hematological malignancies: prevalence, co-pathogens, course and outcome. <i>Infection</i> , 2016 , 44, 491-7	5.8	22
49	Reduced-dose ICE chemotherapy + rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1633-9	1.9	11
48	Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. <i>Journal of Clinical Oncology</i> , 2016 , 34, 501-8	2.2	49
47	Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1382-8	1.9	5
46	TLR9-Regulated IL10 Mediates Immune Inhibitory Activity of Chronic Lymphocytic Leukemia B-Cells. <i>Blood</i> , 2016 , 128, 4377-4377	2.2	1
45	Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series. <i>Blood</i> , 2016 , 128, 5699-5699	2.2	1
44	Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1. <i>Blood</i> , 2016 , 128, LBA-6-LBA-6	2.2	24
43	Does molecular analysis increase the efficacy of bronchoalveolar lavage in the diagnosis and management of respiratory infections in hemato-oncological patients?. <i>International Journal of Infectious Diseases</i> , 2016 , 50, 48-53	10.5	9
42	Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study. <i>British Journal of Haematology</i> , 2016 , 175, 884-891	4.5	10
41	Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study. <i>British Journal of Haematology</i> , 2016 , 172, 89-96	4.5	25
40	Integration of CT-Based Measurements into Surveillance PET/CT in Patients with Diffuse Large B Cell Lymphoma. <i>Israel Medical Association Journal</i> , 2016 , 18, 411-417	0.9	2

39	Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice. <i>Clinical Cancer Research</i> , 2015 , 21, 3853-61	12.9	16
38	Management of Hematologic Malignancies: Special Considerations in Pregnant Women. <i>Drugs</i> , 2015 , 75, 1725-38	12.1	53
37	Impaired migration capacity in monocytes derived from patients with Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , 2015 , 55, 180-6	2.1	9
36	Respiratory Infections and Activity of Anti-Flu Vaccine in Patients with Lymphoma and Multiple Myeloma. <i>Blood</i> , 2015 , 126, 4617-4617	2.2	
35	Different Sources of Stromal Cells Diversely Affect Survival and Trafficking of Mantle Cell Lymphoma Cells. <i>Blood</i> , 2015 , 126, 2670-2670	2.2	
34	Management of acute myeloid leukemia during pregnancy. <i>Future Oncology</i> , 2014 , 10, 1407-15	3.6	7
33	Development of multifocal leukoencephalopathy in patients undergoing allogeneic stem cell transplantation-can preemptive detection of John Cunningham virus be useful?. <i>International Journal of Infectious Diseases</i> , 2014 , 26, 107-9	10.5	11
32	Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1782-91	2.2	69
31	Non-Hodgkin lymphomas in pregnancy: tackling therapeutic quandaries. <i>Blood Reviews</i> , 2014 , 28, 213-2011.1	11.1	16
30	Dendritic cell cancer vaccines: from the bench to the bedside. <i>Rambam Maimonides Medical Journal</i> , 2014 , 5, e0024	1.8	9
29	Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy. <i>Blood</i> , 2014 , 124, 4471-4471	2.2	11
28	Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2014 , 124, 78-78	2.2	19
27	BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial. <i>Blood</i> , 2014 , 124, 950-950	2.2	11
26	Risk of Progression and Survival in Newly Diagnosed Multiple Myeloma Patients Non-Responsive to Bortezomib-Based Induction Therapy: an Observational Multicenter International Study. <i>Blood</i> , 2014 , 124, 3488-3488	2.2	
25	Autologous Stem Cell Transplantation for Primary Mediastinal B Cell Lymphoma in the Rituximab Era: A Retrospective Study By the EBMT Lymphoma Working Party. <i>Blood</i> , 2014 , 124, 1195-1195	2.2	1
24	Elevated Involved Light Chains Discordant to the Increase of the Involved Heavy Chains Identifies a Subset of Multiple Myeloma Patients with Worse Outcome. <i>Blood</i> , 2014 , 124, 2132-2132	2.2	
23	Efficacy and Safety of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Multiple Myeloma: A Retrospective Israeli Multi-Site Cohort Study. <i>Blood</i> , 2014 , 124, 3989-3989	2.2	
22	High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study. <i>Blood</i> , 2014 , 124, 2526-2526	2.2	1

21	Busulfan Fludarabine Vs. Busulfan Cyclophosphamide As a Preparative Regimen Prior to Allogeneic Hematopoietic Cell Transplantation Systematic Review and Meta-analysis. <i>Blood</i> , 2014 , 124, 3872-3872	2.2	1
20	Anti-CD20 monoclonal antibodies: beyond B-cells. <i>Blood Reviews</i> , 2013 , 27, 217-23	11.1	38
19	A subset of CD8+ T cells acquiring selective suppressive properties may play a role in GvHD management. <i>Transplant Immunology</i> , 2013 , 28, 57-61	1.7	8
18	Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2013 , 88, 400-5	7.1	76
17	Acute Myeloid Leukemia Diagnosed During Pregnancy: Facing Challenges. Systematic Review and Analysis Of 174 Reported Cases. <i>Blood</i> , 2013 , 122, 1421-1421	2.2	1
16	Integration Of CT-Based Measurements Into PET Assessment Significantly Improves The Positive Predictive Value Of Surveillance FDG PET/CT In Patients With Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2013 , 122, 4296-4296	2.2	
15	High-Dose Cyclophosphamide In Combination With G-CSF Versus G-CSF Alone For Mobilization Of Hematopoietic Stem Cells After Induction Therapy Including Velcade, Cyclophosphamide and Dexacort. <i>Blood</i> , 2013 , 122, 5369-5369	2.2	
14	Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors. <i>Annals of Hematology</i> , 2012 , 91, 215-21	3	12
13	Final Results of the BP22333 Study Demonstrate Non-Inferior Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Administration of Rituximab Compared with Intravenous (IV) Administration As Maintenance Therapy in Patients with Follicular Lymphoma (FL). <i>Blood</i> , 2012 , 120, 1641-1641	2.2	7
12	Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 [EMERGE] Study. <i>Blood</i> , 2012 , 120, 905-905	2.2	5
11	Absolute Monocyte Count At Diagnosis Is a Poor Prognostic Factor and Impacts Survival in Diffuse Large B-Cell Lymphoma: A Collaborative Multi-Center Study Involving 1026 Patients.. <i>Blood</i> , 2012 , 120, 2651-2651	2.2	
10	(18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 25-30	8.9	292
9	Not All Positive Interim PET/CT Scans Are Reliably Predictive for Progression Free Survival in Hodgkin Lymphoma (HL) Patients. A Proposed Model for a Functional Scoring Scale.. <i>Blood</i> , 2008 , 112, 1452-1452	2.2	1
8	Fusion Cell Vaccination in Conjunction with Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and Is Associated with Responses in Patients with Multiple Myeloma. <i>Blood</i> , 2008 , 112, 826-826	2.2	1
7	Induced CD4+CD25+ FOXP-3+ and CD8+CD25+ FOXP-3+t Cells Exhibit a Concurrent Expression of Effector and Selective Suppressive Capacities. <i>Blood</i> , 2008 , 112, 3501-3501	2.2	
6	Allogeneic Stem Cell Transplantation (ASCT) in CML with Partial T-Cell Depletion, No Prophylaxis for Graft-Versus-Host Disease (GvHD) and Preemptive DLI for Patients with Post-Transplant Minimal Residual Disease (MRD): An Alternative Approach in CML Transplantation with Low Morbidity and Long Term Disease Free Survival. <i>Blood</i> , 2006 , 108, 318-318	2.2	1
5	Conventional allograft and autograft in low grade lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2005 , 18, 113-28	4.2	3
4	Prognostic factors in acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2005 , 12, 62-7	3.3	30

3	Use of Dendritic Cells Versus Peripheral Blood Lymphocytes To Segregate Alloreactive and Regulatory T Cells during Allogeneic Transplantation.. <i>Blood</i> , 2005 , 106, 5244-5244	2.2
2	CA-125 as a Marker for the Early Diagnosis of Hepatic Veno-Occlusive Disease Following Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2004 , 104, 1138-1138	2.2
1	Correlation Between BNT162b2 mRNA Covid-19 Vaccine-associated Hypermetabolic Lymphadenopathy and Humoral Immunity in Patients With Hematologic Malignancy	2